OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Editorial Board	130
Editorial Board	88
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	81
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	59
Editorial Board	57
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	56
Thiazide-induced hyponatremia	56
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	56
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	51
Genetics of pubertal timing	50
The role of androgens in transgender medicine	48
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	46
Coronavirus disease 2019 and vitamin D	44
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	38
Regulation of bone mass: A splendid Orchestra	37
Editorial Board	35
Sexual health and contraception in the menopause journey	35
Immune checkpoint inhibitor-related thyroid dysfunction	34
Editorial Board	31
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	31
Remnant lipoprotein particles and cardiovascular disease risk	30
Cardiometabolic outcomes of early onset hypogonadism in males	30
Haematological actions of androgens	29
Editorial Board	29
Medullary thyroid cancer - An update	27

Metabolic complications and their mechanisms in patients with craniopharyngioma	27
Non-oestrogen-based and complementary therapies for menopause	27
Type 1 diabetes related to immune checkpoint inhibitors	27
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	26
Radioiodine therapy in the different stages of differentiated thyroid cancer	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
The effect of osteoporosis treatment on bone mass	24
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	24
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	24
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	24
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	23
Approach to patients with elevated low-density lipoprotein cholesterol levels	22
Immune checkpoint inhibitor-related hypophysitis	22
Pathophysiology of thyroid-associated orbitopathy	22
Hyponatraemic encephalopathy	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	21
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	21
Editorial Board	21
Localization in primary hyperparathyroidism	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Editorial Board	20
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	19
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	19
History of androgens and androgen action	19
Diagnosis and treatment of hypernatremia	19
Safety of androgen therapy in men with prostate cancer	19
Editorial Board	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	18
Editorial Board	18
Genotype-phenotype correlations in Graves’ disease	17
Diagnostic algorithm of hyponatremia	17
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	17
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	17
Mortality in craniopharyngiomas: Data from the last two decades	16
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	16
Genetics of anti-Müllerian hormone and its signaling pathway	16
Exercise and physical activity in individuals at risk of fracture	15
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	15
COVID-induced thyroid autoimmunity	15
Preface	15
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	14
Hormone replacement in disorders of sex development, and long-term effects	14
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	13
Strategies for improving the knowledge of patients and carers	13
Chemokines in thyroid autoimmunity	13
Anaplastic thyroid cancer: An update	13
Care quality improvement in differences of sex development	13
The epidemiology of disorders of sex development	13
Paraneoplastic autoimmune hypophysitis: An emerging concept	12
Preface	12

Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	12
Editorial Board	12
The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury	11
Ectopic craniopharyngiomas	11
Outcomes of pregnancies complicated by type 2 diabetes	11
Covid-19 and endocrinology	11
Addressing the social determinants of adverse outcomes in pregestational diabetes	11
Editorial Board	10
Editorial Board	10
The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I	10
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess	10
New potential treatment options for syndrome of inappropriate antidiuresis	10
How best to monitor the specific side effects of medical treatments of Cushing’s disease	10
Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists	10
SARS-CoV-2 infection and its effects on the endocrine system	10
Surgical treatment of thyroid cancer: Established and novel approaches	9
Long-term thionamide antithyroid treatment of Graves' disease	9
Endocrine abnormality in paraneoplastic syndrome	9
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	9
Choosing the best systemic treatment sequence for control of tumour growth in gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): What is the recent evidence?	9
Quality of life in thyroid cancer	9
Treatment of chronic hyponatremia and controversy about osmotic demyelination syndrome	9
Androgen-based therapies in women	8
Real-world value of cabergoline in the treatment of acromegaly	8
Regulation of bone mass in endocrine diseases including diabetes	8
Management of patients with statin intolerance	8
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	8
Adolescent primary hyperparathyroidism	8
Editorial Board	7
COVID-19 vaccination and thyroiditis	7
Genetics of 46,XY gonadal dysgenesis	7
Preface	7
Appropriate use of morphological imaging for assessing treatment response and disease progression of neuroendocrine tumors	7
Current medical treatment and perspective in gonadotroph tumors	7
Newly detected diabetes during the COVID-19 pandemic: What have we learnt?	7
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	7
Mild traumatic brain injury as a cause of adult growth hormone deficiency: Diagnosis and treatment	6
Novel androgen therapies including selective androgen receptor modulators	6
Outcomes of recombinant growth hormone therapy in the traumatic brain injury population: A scoping review	6
Burosumab: Current status and future prospects	6
Androgens part 2: Emerging areas	6
Hyponatraemia and cancer	6
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model	6
Inherited fibroblast growth factor 23 excess	6
Vitamin D deficiency or resistance and hypophosphatemia	6
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	5
Hypothalamus-sparing surgery in craniopharyngiomas: Oncological and hypothalamic long-term outcomes	5
New advances in menopause symptom management	5
Pituitary dysfunction due to sports injuries	5
Updates in histopathological classification and tissue biomarkers of digestive neuroendocrine neoplasms: What the clinician should know	5
Traumatic brain injury and hypopituitarism	5
Morbidity and mortality in men: Role of androgens	5
Heritable hyperparathyroidism: Genetic insights and clinical implications	5
Pituitary neuroendocrine tumors: from old treatments to innovations, from efficacy to tolerance, from benignity to carcinomas, where do we stand now?	5
Traumatic brain injury, abnormal growth hormone secretion, and gut dysbiosis	5
Pituitary and SARS CoV-2: An unremitting conundrum	5
Tumor-induced osteomalacia: An overview	5
Innovative therapeutics in acromegaly	5
Genetics of ovarian insufficiency and defects of folliculogenesis	5
Management of non-hepatic distant metastases in neuroendocrine neoplasms	5
Diagnosis of gestational diabetes: Evidence and pitfalls	5
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model	5
Broader impact and outcome of human NR5A1/SF1 variants	4
Primary hyperparathyroidism	4
Androgens, sports, and detection strategies for anabolic drug use	4
The pathophysiology of hypophosphatemia	4
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	4
Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review	4
Editorial Board	4
Genetics of cryptorchidism and testicular regression	4
Premature ovarian insufficiency, early menopause, and induced menopause	4
SDH-related head and neck paragangliomas: Unraveling PET radiomics beyond 18F-FDG	4
Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective	4
Editorial Board	4
Developments in interventional management of hepatic metastases from neuroendocrine tumours	4
Congenital primary hyperparathyroidism	4